Bioline RX Ltd  

(Public, NASDAQ:BLRX)   Watch this stock  
Find more results for BLRX
1.00
-0.01 (-0.99%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.99 - 1.04
52 week 0.85 - 3.28
Open 1.00
Vol / Avg. 38,692.00/220,312.00
Mkt cap 55.09M
P/E     -
Div/yield     -
EPS -1.21
Shares 54.82M
Beta 1.87
Inst. own     -
Mar 14, 2016
BioLineRx to present at the 9th Annual European Life Science CEO Forum and Exhibition Forum in Zurich, Switzerland on March 15-16, 2015 - 8:00PM EDT - Add to calendar
Mar 13, 2016
BioLine RX Ltd at ROTH Conference Add to calendar
Feb 7, 2016
BioLineRx to present at BioCEO in New York City, NY on February 8-9, 2015 - 7:00PM EST - Add to calendar
Jan 10, 2016
BioLineRx to present at Biotech Showcase in San Francisco, CA January 11-13, 2016
Jan 10, 2016
BioLineRx to attend the 34rd Annual JP Morgan Healthcare Conference
Dec 1, 2015
BiolineRx will present at the LD Micro Main Event in Los Angeles, CA on December 2, 2015
Nov 16, 2015
Q3 2015 BioLine RX Ltd Earnings Call
Nov 16, 2015
Q3 2015 BioLine RX Ltd Earnings Release
More events from DailyFinance »    

Address

2 HaMa'ayan Street Modi'in Technology Park
MODIIN, 7177871
Israel
+972-8-6429100 (Phone)
+972-8-6429101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Officers and directors

Aharon Schwartz Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Kinneret Savitsky Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Philip Adam Serlin Chief Financial Officer, Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Moshe Phillip M.D. Vice President of Medical Affairs and Senior Clinical Advisor
Age: 59
Bio & Compensation  - Reuters
David Malek Vice President - Business Development
Age: 35
Bio & Compensation  - Reuters
Leah Klapper General Manager, BioLine Innovations Jerusalem
Bio & Compensation  - Reuters
Michael J. Anghel Director
Age: 76
Bio & Compensation  - Reuters
Jacob Friedman Director
Age: 44
Bio & Compensation  - Reuters
Raphael Hofstein Director
Age: 63
Bio & Compensation  - Reuters
Sandra Panem Ph.D. Director
Age: 68
Bio & Compensation  - Reuters